Device costs are a huge portion of surgical bills, and 60 percent of physicians say doctors have the most influence over device purchasing decisions currently, according to the "Deloitte 2013 Survey of U.S. Physicians: Physician perspectives about health care reform and the future of the medical profession."
The respondents who feel physicians have the most influence over device purchasing thought it would stay that way for the next three to five years. Here are three more statistics from the report:
1. Within the bundled payment structure, nearly 50 percent of physicians believe the most important evidence for purchasing medical technology, beyond safety and efficacy, is the "potential reduction in instances of needed care."
2. Around 70 percent of physicians feel physician-led, peer review of new medical technologies is the leading best practice in the selection and purchase of medical technology.
3. The use of evidence-based guidelines was the second leading best practice for choosing and purchasing medical technologies.
More Articles on Supply Chain:
31 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in March
Regentis Biomaterials Doubles Scope of Orthopedic Implant Trial
Stryker Names William Jellison CFO
The respondents who feel physicians have the most influence over device purchasing thought it would stay that way for the next three to five years. Here are three more statistics from the report:
1. Within the bundled payment structure, nearly 50 percent of physicians believe the most important evidence for purchasing medical technology, beyond safety and efficacy, is the "potential reduction in instances of needed care."
2. Around 70 percent of physicians feel physician-led, peer review of new medical technologies is the leading best practice in the selection and purchase of medical technology.
3. The use of evidence-based guidelines was the second leading best practice for choosing and purchasing medical technologies.
More Articles on Supply Chain:
31 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in March
Regentis Biomaterials Doubles Scope of Orthopedic Implant Trial
Stryker Names William Jellison CFO